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Workflow of CRISPR-
Cas9 screen of human 
glioblastoma stem-like 
cells (GSCs) and human 
neural progenitors (top 
panel). the related 
kinases PKMYT11 and 
WEE1 act redundantly to 
phosphorylate CDK1 on 
T14 and Y15 to prevent 
premature mitotic entry 
(bottom panel). 
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A widely held assumption of the burgeoning field of precision oncology is that identification of driver 
mutations present in tumors allied with computational analysis of other descriptive genomic datasets 
is sufficient to predict therapeutic targets. However, directly identifying cancer-specific vulnerabilities 
requires genetic manipulation of genes in patient-derived samples. This has not been a 
straightforward task until the emergence of a gene editing technology known as CRISPR, which was 
hailed by Science magazine as the breakthrough of the year of 2015. A Fred Hutch study led by Drs. 
Chad Toledo and Yu Ding in the Paddison Laboratory (Human Biology and Public Health Sciences 
Divisions), in collaboration with the Olson (Clinical Research Division) and Clurman (Human Biology 
and Clinical Research Divisions) Labs, leveraged the CRISPR technology to perform genome-wide 
screens for genes that when deleted, caused lethality in human glioblastoma stem cells (GSCs), but 
not in normal neural stem and progenitor cells (NSCs). This study, published in the journal Cell 
Reports, revealed that two kinases, PKMYT1 and WEE1, act redundantly in NSCs but not GSCs and 
provides a rationale for pursuing PKMYT1 inhibitors. 
The investigators first tested the efficacy of a lentiviral-based delivery of a CRISPR-Cas9 system to 
target a reporter gene (GFP), a non-essential endogenous gene (TP53) or an essential endogenous 
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gene (MCM2). All three were efficiently targeted in both GSCs and NSCs. This provided the authors 
confidence to perform genome-wide screens in two GSC (0131 and 0827) and two NSC isolates 
(CB660 and U5) using a lentiviral pool containing a CRISPR library containing 64,751 single guide 
RNA (sgRNAs) targeting 18,080 genes. Deep sequencing of sgRNAs before and after three weeks 
of growth in self-renewing conditions, followed by empirical analysis of digital gene expression in the 
biostatistical analysis package R was performed to identify candidate essential genes. The scientists 
next wondered whether their screen hits would be enriched for genes and pathways commonly 
altered in glioblastoma yet were surprised to find that only ten GSC-specific lethals out of a total of 
946 overlapped with core glioblastoma pathways. Said Dr. Patrick Paddison, "We went into this 
study thinking we would validate the notion that genomic characterization (e.g., deep sequencing) of 
patient tumor samples would be predictive of "actionable" therapeutic targets.  However, the screen 
results clearly demonstrate that this is not the case.  The genomic alterations (e.g., "driver" 
mutations) did not predict therapeutic targets, as defined by this screening technique.  Instead, we 
identified 100s of candidate therapeutic targets that are off the radar screen of conventional 
precision oncology.  The results highlight the need to experiment directly in patient samples to 
identify patient tailored therapeutic approaches." 
Both in vitro and in vivo validation of candidate genes revealed the kinase PKMYT1 as the top 
candidate, as it was required for the viability of eight out of ten GSC lines tested. PKMYT1 is a 
kinase that phosphorylates CDK1 (see figure), and at least in Drosophila, acts redundantly with the 
related kinase WEE1 to prevent premature entry into mitosis. With this in mind, the investigators 
tested the effects of depleting PKMYT1 and WEE1 either alone or in combination by monitoring the 
mitotic transit times (MTT) of NSCs or GSCs using time-lase microscopy. In NSCs, inhibition of 
either PKMYT1 or WEE1 alone resulted only in modest increases in MTT (from 37min to 47-51min). 
However, combined loss of PKMYT1 and WEE1 led to average MTTs of more than 100min. In 
contrast, inhibition of either PKMYT1 or WEE1 alone led to dramatic increases in MTTs when the 
same set of experiments was repeated using GSCs, suggesting that PKMYT1 and WEE1 act 
redundantly in NSCs but not GSCs. Finally, the authors were able to recapitulate PKMYT1 sensitivity 
in NSCs by concurrently activating the EGFR and AKT, known glioma driver mutation pathways in 
immortalized NSCs. In conclusion, this study showed both the power and feasibility of CRIPSR-
based genome-wide screens using patient-derived samples to identify genes that are essential in 
transformed cells but not in normal cells. "We are now putting PKMYT1 into our inhibitor 
development pipeline, which Dr. Jim Olson leads.  Our hope is to have a therapeutic strategy in 
clinical trials within the next 5 years," said Dr. Paddison. 
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